About the UK Cystic Fibrosis Gene Therapy Consortium
The Consortium groups are based in three of the leading UK universities. Prior to the formation of the Consortium each group had conducted at least one clinical trial for gene therapy. Therefore, our researchers have been at the forefront of this field for over 20 years.
These sections describe the how the Consortium functions and how we are organised.
Together against CF
In 2001 the UK's three UK's three leading Cystic Fibrosis gene therapy groups joined together as one organisation, the UKCFGTC, to share expertise and funding.
The aim of this collaboration was to bring the three research groups together to focus on a single common goal of making gene therapy for CF a clinical reality.
The Consortium is now the world's largest gene therapy group focused on a single disease, with a combined staff of over 50. Our clinical trial programme is well underway and there are plans to initiate a multi-dose study of our first clinical product in 2012.
This multi-dose trial will be the first ever opportunity to find out if our gene therapy can result in clinical benefit.
University of Oxford: Gene Medicine Group
Imperial College London: Department of Gene Therapy, National Heart & Lung Institute
Information for Patients on Our Clinical Trial
Consortium Members' Internal Website
Medical Futures Innovation Award 2011